Clinical trial
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
NCT00216047 · Hoosier Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00216047 |
|---|---|
| Title | PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer |
| Official title | A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80 |
| Lead sponsor | Hoosier Cancer Research Network, Other |
| Collaborators | Novartis Pharmaceuticals Industry Walther Cancer Institute |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | PTK787, Trastuzumab |
| Enrollment | 7 |
| Start date | Jan 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 9, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: